Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

近日，国际权威学术期刊Journal of Translational Medicine在线发表了博雅生命旗下博雅医药与天津市第一中心医院血液科等单位合作的研究成果，论文标题为《Knockout IL4I1 affects macrophages ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

US clinical-stage biotech CARGO Therapeutics’ shares plummeted more than 75% to $3.23 yesterday, after it announced that it has elected to discontinue FIRCE-1, a Phase II clinical study of ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...